Bina & ADI Negev-Nahalat Eran Rehabilitation Hospital collaboration

We are thrilled to collaborate with this pioneering facility, which opened in 2022 as the first dedicated rehabilitation hospital in Israel's Negev region. This innovative center is making significant developments in addressing rehabilitation needs, offering specialized services in orthopedic, neurological, and soon, geriatric care.

Our collaboration focuses on advancing research and care for individuals with disabilities and reflects our commitment to addressing the complex challenges associated with disabilities.

More News

Meet Yaron Penn, Collaboration Manager at Bina

We congratulate Dr. Yaron Penn for joining the Bina team!
Yaron is a Deep-tech innovator and executive with a PhD in Neuroscience from the Weizmann Institute of Science. Specialist in Brain-Computer Interfaces, Neural Networks, Bio-Analytics, Real-time Control Systems, Remote Sensing, IoT, Full-Stack Edge Computing, Controlled Environment Agriculture (CEA), Closed-Loop Systems, Automation, Robotics, and imaging, with extensive experience in the design, initiation, implementation and management of interdisciplinary systems.

Bina Impact report 2024

We share Bina’s 2024 Impact Report with our followers, showcasing a year of innovative research and meaningful collaborations at the Weizmann Institute of Science: Bina_Annual_Report_SM_2025.pdf

If you wish to take part in our activities, whether you’re a potential partner or an expert advisor in your field, reach out to discuss collaboration opportunities or explore how you can contribute to our mission.

ABC CHATS - Dr. Alon Seri levy from Sol-Gel

From Academic Research to FDA-Approved Drugs: Insights from Alon Seri-Levy

We had the privilege of attending an inspiring talk by Alon Seri-Levy, CEO of Sol-Gel Technologies at the Bina 'ABC' chat.
Alon shared his remarkable journey, transitioning from the chemistry bench at Prof. David Avnir, The Hebrew University of Jerusalem to building a successful company that develops FDA-approved treatments.
His story is a testament to determination, commitment, and focus, even when faced with challenges like limited industry knowledge or costly missteps.